Daily Endocrinology Research Analysis
Three impactful endocrinology studies stood out: a GRADE trial analysis shows glucose-lowering drugs differentially modulate distinct components of β-cell function; exome sequencing in early-onset primary ovarian insufficiency reveals complex genetic architecture with novel candidate genes; and autopsy data link aldosterone synthase–positive adrenal lesions to increased risk of sudden death. Together they advance precision therapeutics, genomic diagnosis, and cardio-endocrine risk stratification
Summary
Three impactful endocrinology studies stood out: a GRADE trial analysis shows glucose-lowering drugs differentially modulate distinct components of β-cell function; exome sequencing in early-onset primary ovarian insufficiency reveals complex genetic architecture with novel candidate genes; and autopsy data link aldosterone synthase–positive adrenal lesions to increased risk of sudden death. Together they advance precision therapeutics, genomic diagnosis, and cardio-endocrine risk stratification.
Research Themes
- Precision pharmacophysiology of type 2 diabetes therapies
- Genomic architecture of reproductive endocrinology disorders
- Adrenal endocrinology and cardiovascular sudden death risk
Selected Articles
1. Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
In GRADE, liraglutide produced the largest improvements in insulin secretion rate, glucose sensitivity, and potentiation, while sitagliptin mainly improved glucose sensitivity; glimepiride transiently boosted early insulin response, and insulin glargine most increased rate sensitivity. Despite initial gains at 1 year, β-cell function declined across all treatments, and lower β-cell function predicted earlier glycemic failure.
Impact: This work dissects differential physiologic effects of widely used T2D drugs on β-cell function at scale, informing precision therapy beyond A1C. It also quantifies progressive β-cell decline, underscoring the need for strategies to preserve function.
Clinical Implications: Drug choice can be tailored to targeted β-cell deficits: GLP-1RA for enhancing secretion and sensitivity, DPP-4i for glucose sensitivity, basal insulin for early-phase dynamics, and cautious use of sulfonylureas given transient effects. Monitoring β-cell function trajectories may help anticipate glycemic failure.
Key Findings
- At year 1, β-cell parameters improved variably across treatments, but declined thereafter for all arms up to year 5.
- Liraglutide produced the largest increases in insulin secretion rate, glucose sensitivity, and potentiation, remaining above baseline at study end.
- Sitagliptin improved glucose sensitivity with modest effects on other parameters; glimepiride transiently increased ISR and rate sensitivity; glargine most increased rate sensitivity.
- Higher model-based β-cell parameters were protective against glycemic failure (A1C >7.5%), independent of treatment.
Methodological Strengths
- Large randomized comparative effectiveness framework (N=4,712) with standardized OGTT-based mathematical modeling.
- Longitudinal assessments at 1, 3, and 5 years with mixed-effects and time-to-event analyses.
Limitations
- Secondary analysis; model-derived β-cell parameters are not direct physiologic measurements.
- All participants were on background metformin, which may limit generalizability to metformin-intolerant populations.
Future Directions: Test whether combination regimens can synergistically sustain specific β-cell domains and evaluate strategies to slow post-year-1 decline; integrate β-cell modeling into adaptive treatment algorithms.
OBJECTIVE: To evaluate how model-based parameters of β-cell function change with glucose-lowering treatment and associate with glycemic deterioration in adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE), β-cell function parameters derived from mathematical modeling of oral glucose tolerance tests were assessed at baseline (N = 4,712) and 1, 3, and 5 years following randomization to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin. Parameters included insulin secretion rate (ISR), glucose sensitivity (insulin response to glucose), rate sensitivity (early insulin response), and potentiation. Linear mixed-effects models were used to compare changes across treatments. With Cox proportional hazards and Classification And Regression Tree (CART) analyses we evaluated associations between model parameters and glycemic failure (A1C >7.5%; 58.5 mmol/mol). RESULTS: β-Cell function parameters increased variably at year 1 across treatments but subsequently declined for all treatments. Statistically significant changes were noted. Liraglutide led to the greatest increases in ISR, glucose sensitivity and potentiation, remaining above baseline at study end. Sitagliptin improved glucose sensitivity, with modest effects on other parameters. Glimepiride temporarily increased ISR and rate sensitivity but minimally increased glucose sensitivity or potentiation. Rate sensitivity increased most with glargine. Higher β-cell function parameters were protective against glycemic deterioration, but treatment did not alter the relationship between these parameters and glycemic outcomes. CONCLUSIONS: Common glucose-lowering medications impact different physiologic components of β-cell function in T2D. Regardless of treatment modality, lower β-cell function associated with early glycemic failure, and β-cell function progressively declined after initial improvement.
2. A Tiered Approach to Exome Sequencing Analysis in Early-Onset Primary Ovarian Insufficiency.
In 149 EO-POI cases, 127 pathogenic/likely pathogenic variants across 74 genes were identified using a tiered exome approach, yielding variants in 64.7% of familial and 63.6% of sporadic cases. Findings highlight both monogenic (notably autosomal recessive in familial cases) and polygenic etiologies, and propose novel candidate genes (e.g., PCIF1, DND1, MEF2A, RXFP3) for further validation.
Impact: This is one of the largest EO-POI sequencing cohorts with a structured analytic framework, revealing complex genetic architecture and new candidate genes, guiding diagnostic panels and research priorities.
Clinical Implications: Genetic testing with a tiered, panel-informed exome approach can identify actionable monogenic causes (particularly in familial EO-POI) and inform counseling, fertility preservation, and surveillance; polygenic signatures suggest future polygenic risk models.
Key Findings
- Identified 127 Category 1/2 variants across 74 genes; detection in 64.7% of familial kindreds and 63.6% of sporadic cases.
- Clear autosomal recessive monogenic etiologies in several familial cases (e.g., STAG3, MCM9, PSMC3IP, YTHDC2, ZSWIM7).
- Proposed Category 3 novel candidate genes, including PCIF1, DND1, MEF2A, MMS22L, RXFP3, C4orf33, and ARRB1.
- Heterozygous variant pathogenicity remains challenging; a substantial subset shows polygenic contributions.
Methodological Strengths
- Tiered analytic framework integrating PanelApp genes with expanded POI-associated genes and enrichment filters.
- Inclusion of both familial and sporadic EO-POI across a specialized referral cohort with uniform exome sequencing.
Limitations
- Variant pathogenicity for heterozygous findings often lacks functional validation and complete segregation data.
- Clinical actionability and penetrance estimates remain uncertain without longitudinal follow-up.
Future Directions: Functional validation of candidate genes, segregation studies in extended families, and development of polygenic risk scores to complement monogenic diagnostics in EO-POI.
CONTEXT: Establishing the genetic basis of early-onset primary ovarian insufficiency (EO-POI, <25 years) is important, but defining variant pathogenicity is challenging. OBJECTIVE: We aimed to elucidate the genetic architecture of EO-POI in a unique, large cohort. Young women with EO-POI (n = 149; n = 31 familial, n = 118 sporadic) attending a specialist reproductive unit were included. Exome sequencing was performed. After filtering, variants were retained that were: (1) rare/novel (minor allele frequency <0.01%); (2) predicted pathogenic/likely pathogenic; and (3) enriched in the cohort. Each variant was assigned to a category: Category 1, variants in Genomics England Primary Ovarian Insufficiency PanelApp genes (n = 69); Category 2, variants in other POI-associated genes (n = 355) or Category 1 variants following unexpected inheritance patterns; and Category 3, homozygous variants in novel candidate POI genes. RESULTS: A total of 127 Category 1 or 2 variants were identified in 74 different genes (heterozygous 30.9%; homozygous 9.4%; polygenic 21.8%). In familial EO-POI, 64.7% (11/17 kindred) had a Category 1 or 2 variant identified (homozygous: STAG3, MCM9, PSMC3IP, YTHDC2, ZSWIM7; heterozygous: POLR2C, NLRP11, IGSF10, PRKD1, PLEC; polygenic: PDE3A, POLR2H, MSH6, CLPP). In sporadic EO-POI, 63.6% (n = 75/118) women had a variant identified: 21.2% (n = 25) Category 1; 42.4% (n = 50) Category 2. Novel POI candidate genes (Category 3) included PCIF1, DND1, MEF2A, MMS22L, RXFP3, C4orf33, and ARRB1. CONCLUSION: The genetic basis of EO-POI is complex and affected genes span ovarian developmental processes from fetal life to adulthood. Establishing the pathogenicity of individual heterozygous variants can be challenging. However, some women have clear monogenic causes, particularly in familial POI with autosomal recessive inheritance. Others have potential polygenic causes. We describe novel candidate POI genes warranting further exploration.
3. Adrenal aldosterone synthase (CYP11B2) histopathology and its association with disease-induced sudden death: a cross-sectional study.
Among 403 autopsies, aldosterone-producing adenomas/nodules (CYP11B2-positive) were found in 6.2% overall and were significantly enriched in disease-induced and cardiac sudden deaths, with ORs 6.47 and 10.68, respectively. Findings support a potential role of undiagnosed primary aldosteronism in sudden death.
Impact: This study links adrenal aldosterone-producing pathology with sudden death risk, bridging endocrine hypertension and fatal cardiovascular events, and motivating proactive screening for primary aldosteronism.
Clinical Implications: Heightened consideration of primary aldosteronism screening in patients with resistant hypertension or unexplained cardiovascular morbidity may prevent fatal events. The data support the value of timely case-finding and treatment (e.g., mineralocorticoid receptor antagonists or adrenalectomy) to reduce sudden death risk.
Key Findings
- CYP11B2-positive aldosterone-producing adenomas/nodules were present in 25/403 (6.2%) autopsies and associated with myocardial infarction and atherosclerosis.
- APA/APN were significantly more frequent in DSD (8.9%) and sudden cardiac death (8.8%) than in nDSD (1.4%).
- APA/APN independently explained DSD (OR 6.47, 95% CI 1.40–29.88) and SCD (OR 10.68, 95% CI 2.02–56.43).
- Additional adrenal findings included two pheochromocytomas and three adrenal metastases.
Methodological Strengths
- Consecutive autopsy cohort with standardized CYP11B2 immunohistochemistry to identify aldosterone-producing lesions.
- Comparison against a non-disease-induced sudden death reference group and multivariable modeling of associations.
Limitations
- Cross-sectional autopsy design precludes causal inference and may be subject to selection biases.
- Single-country cohort; premortem clinical data and aldosterone status were unavailable.
Future Directions: Prospective clinical studies linking biochemically confirmed primary aldosteronism to arrhythmic and mortality outcomes, and evaluation of whether targeted treatment mitigates sudden death risk.
BACKGROUND: Unidentified cardiovascular risk factors may account for approximately half of sudden deaths, a devastating event with limited preventive tools. We investigated whether adrenal histopathology suggestive of primary aldosteronism, pheochromocytoma, or adrenal masses could explain part of the risk for disease-induced sudden death (DSD). METHODS: In this study, autopsies and histopathological analyses, including aldosterone synthase staining of adrenal glands, were performed on 403 consecutive individuals who experienced sudden death. These individuals were classified into 258 cases of DSD and 144 deaths caused by trauma, suicide, or intoxication, i.e., non-disease-induced sudden death (nDSD). This trial was registered at ClinicalTrials.gov (NCT05446779). FINDINGS: Adrenal histopathology revealed changes in 31 (7.7%) subjects of the cohort. Of these, the most prevalent findings [25 (6.2%)] were aldosterone-producing adenomas (APA) or nodules (APN), which were associated with myocardial infarction and atherosclerosis at autopsy. Individuals in the DSD group and the subgroup with sudden cardiac death (SCD) were more likely to have APA or APN than individuals in the nDSD group [23 (8.9%) vs. 2 (1.4%), p = 0.002; 16 (8.8%) vs. 2 (1.4%), p = 0.003, respectively]. APA or APN were explanatory factors for DSD (odds ratio [OR] 6.47, 95% confidence interval [CI] 1.40-29.88, p = 0.017) and SCD (OR 10.68, 95% CI 2.02-56.43, p = 0.005). Other findings included two pheochromocytomas, one bilateral adrenal metastasis, and two unilateral adrenal metastases. INTERPRETATION: In this exploratory study, APA or APN were more frequently seen in DSD and SCD than nDSD cases. Whether primary aldosteronism constitutes a novel risk factor for sudden death warrants further study. FUNDING: Finnish State Research funds and independent research foundations: Aarne Koskelo Foundation, the Finnish Kidney Foundation, and the Finnish Foundation for Cardiovascular Research.